Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$35.91−0.53 (-1.45%)
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
Nektar Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Nektar Therapeutics's total assets was $1.10B at Jun 30, 2026. For fiscal 2025 it was $280.41M, down 7.7% from the year before. Over ten years it grew -5.6% a year on average. The highest annual figure on record is $2.15B in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $280.41M | -7.7% |
| FY2024 | Dec 31, 2024 | $303.85M | -23.7% |
| FY2023 | Dec 31, 2023 | $398.03M | -44.0% |
| FY2022 | Dec 31, 2022 | $710.60M | -36.4% |
| FY2021 | Dec 31, 2021 | $1.12B | -27.4% |
| FY2020 | Dec 31, 2020 | $1.54B | -22.2% |
| FY2019 | Dec 31, 2019 | $1.98B | -8.0% |
| FY2018 | Dec 31, 2018 | $2.15B | +322.5% |
| FY2017 | Dec 31, 2017 | $508.87M | -10.5% |
| FY2016 | Dec 31, 2016 | $568.87M | +14.1% |
| FY2015 | Dec 31, 2015 | $498.64M | +12.9% |
| FY2014 | Dec 31, 2014 | $441.62M | +1.6% |
| FY2013 | Dec 31, 2013 | $434.53M | -12.7% |
| FY2012 | Dec 31, 2012 | $497.79M | -17.9% |
| FY2011 | Dec 31, 2011 | $606.55M | +16.4% |
| FY2010 | Dec 31, 2010 | $521.23M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.10B | +327.4% |
| Q4 FY2025 | Dec 31, 2025 | $280.41M | -7.7% |
| Q3 FY2025 | Sep 30, 2025 | $301.35M | -2.1% |
| Q2 FY2025 | Jun 30, 2025 | $207.53M | -39.6% |
| Q1 FY2025 | Mar 31, 2025 | $256.24M | -35.3% |
| Q4 FY2024 | Dec 31, 2024 | $303.85M | -23.7% |
| Q3 FY2024 | Sep 30, 2024 | $307.97M | -30.4% |
| Q2 FY2024 | Jun 30, 2024 | $343.33M | -30.5% |
| Q1 FY2024 | Mar 31, 2024 | $396.01M | -29.5% |
| Q4 FY2023 | Dec 31, 2023 | $398.03M | -44.0% |
| Q3 FY2023 | Sep 30, 2023 | $442.24M | -43.4% |
| Q2 FY2023 | Jun 30, 2023 | $494.28M | -42.7% |
| Q1 FY2023 | Mar 31, 2023 | $561.74M | -45.1% |
| Q4 FY2022 | Dec 31, 2022 | $710.60M | -36.4% |
| Q3 FY2022 | Sep 30, 2022 | $781.01M | -38.9% |
| Q2 FY2022 | Jun 30, 2022 | $861.99M | -37.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.02B | -29.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.12B | -27.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.28B | -15.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.37B | -14.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.46B | -22.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.54B | -22.2% |
| Q3 FY2020 | Sep 30, 2020 | $1.51B | -27.8% |
| Q2 FY2020 | Jun 30, 2020 | $1.59B | -24.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.89B | -12.9% |
| Q4 FY2019 | Dec 31, 2019 | $1.98B | -8.0% |
| Q3 FY2019 | Sep 30, 2019 | $2.09B | -7.1% |
| Q2 FY2019 | Jun 30, 2019 | $2.10B | -9.2% |
| Q1 FY2019 | Mar 31, 2019 | $2.17B | +336.1% |
| Q4 FY2018 | Dec 31, 2018 | $2.15B | +322.5% |
| Q3 FY2018 | Sep 30, 2018 | $2.25B | +286.4% |
| Q2 FY2018 | Jun 30, 2018 | $2.31B | +386.1% |
| Q1 FY2018 | Mar 31, 2018 | $496.79M | -6.0% |
| Q4 FY2017 | Dec 31, 2017 | $508.87M | -10.5% |
| Q3 FY2017 | Sep 30, 2017 | $582.06M | +36.9% |
| Q2 FY2017 | Jun 30, 2017 | $475.86M | +2.8% |
| Q1 FY2017 | Mar 31, 2017 | $528.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $568.87M | – |
| Q3 FY2016 | Sep 30, 2016 | $425.10M | – |
| Q2 FY2016 | Jun 30, 2016 | $463.10M | – |
See a number that looks wrong?